Results of the phase II KEYNOTE-158 study demonstrated the efficacy of the PD-1 inhibitor pembrolizumab in cervical cancer which led to Food and Drug Administration (FDA) approval (26). This evidence concerns the gene PDCD1 and cervical carcinoma.